Tata Consultancy Services has launched an agentic AI platform designed specifically for pharmaceutical drug development, targeting the operational bottlenecks that slow clinical trials in heavily regulated environments.
The TCS ADD AgentHub platform uses AI agents to handle tasks such as case intake, medical coding, quality review, literature analysis and study support. Each action runs within a framework of human oversight, governance, auditability and lifecycle control, according to the company.
Pharmaceutical companies face a delicate balance: they need AI's efficiency gains, but regulatory compliance demands rigorous audit trails at every stage of drug development. TCS says its platform is built for exactly that constraint.
Role-based AI workforce
The platform is built on the TCS ADD suite and uses what the company calls AI Workers, Assistants and Tools. The model is role-based and designed to work alongside human experts rather than replace them.
"TCS ADD AgentHub introduces a role-based AI workforce that supports key drug development functions across pharmacovigilance and clinical operations," said Rachna Malik, Global Head of TCS ADD. "These agents perform specialised tasks while operating within a framework of human oversight, governance, auditability and lifecycle control."
Malik said the goal is not to replace medical and scientific professionals but to cut the time they spend on repetitive work. "Compared with traditional human-led processes, AgentHub helps organisations scale operations, reduce repetitive manual effort, improve consistency and enable experts to focus on higher-value scientific and medical decision-making."
For professionals working in AI for Healthcare, the platform's approach reflects a broader shift toward AI systems that must prove their reliability to regulators, not just perform well in testing.
Measured results from production deployments
TCS reports measurable outcomes from existing deployments. According to the company, AgentHub has delivered up to 40% efficiency gains in clinical data management activities, up to 30% reduction in clinical study build effort through metadata-driven automation, and up to 30% cost savings in Individual Case Safety Report processing.
These results come from earlier enterprise deployments of AI in production environments, not pilot programs. "A lot of our learnings have come from the large-scale deployment of earlier generations of AI in production, directly addressing past shortcomings in value realisation," Malik said.
She added that key solutions available through AgentHub accelerate trial setup and submission timelines, "where the business impact is highest."
Architecture built for auditability
The platform's technical architecture is collaborative. Intelligent agents manage embedded workflows while human clinical professionals retain final control over medical and regulatory decisions. TCS says this model is designed for environments where auditability is mandatory.
"TCS ADD AgentHub is an enterprise-ready, trusted AI platform that enables our customers to accelerate drug development using agentic AI at scale," said Debashis Ghosh, President of Life Sciences and Healthcare at TCS. "It enables a shift from reactive to proactive, scalable and audit-ready operations amidst an ever-changing regulatory environment."
Ghosh said TCS's strategy is to move toward what it calls autonomous enterprise functions, "where an AI workforce operates alongside humans to drive innovation and improve patient safety."
For professionals in regulatory roles, the platform's emphasis on audit trails and human sign-off reflects the compliance requirements they already work with daily. Training in AI for Regulatory Affairs Specialists covers similar ground: how to apply AI without losing the documentation and control that regulators expect.
Why this matters for healthcare professionals
For clinicians, safety reviewers and clinical operations staff, the practical takeaway is that AI agents are entering their workflows now, and the systems that succeed will be those that respect existing regulatory structures. The 40% efficiency gains TCS cites in clinical data management translate directly into less time on coding, intake and review tasks, and more time on scientific judgment.
The other implication is skills-related. As platforms like AgentHub take over repetitive tasks, the value of professionals who can oversee AI outputs, interpret results and make final medical decisions increases. Understanding how these systems operate, and where their limits are, is becoming part of the job.
Your membership also unlocks:
